Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04651-xSource: DataRank Database

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers is a research paper published in Cancer Chemotherapy and Pharmacology (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.16)OA: greenTopics (62)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Naoko Takebe ORCID,Alice P. Chen ORCID,Shivaani Kummar ORCID,Richard Piekarz ORCID,Brian F. Kiesel ORCID

Live enrichment

PubMed:38483557 PMC:PMC11390298 OpenAlex:https://openalex.org/W4392807109

National Institutes of Health

Grant: UM1 CA186690

NCI NIH HHS

Grant: P30 CA047904

NCI NIH HHS

Grant: U24 CA247643

NCI NIH HHS

Grant: R50 CA211241

National Institutes of Health

Grant: 5U24CA247643-05

PITT-CAL ETCTN PK Resource Laboratory

National Institutes of Health

Grant: 5R50CA211241-02

Cancer Pharmacokinetics Research Specialist

National Institutes of Health

Grant: 5UM1CA186690-09

NCI ETCTN Pittsburgh Cancer Consortium (PCC)

National Institutes of Health

Grant: 3P30CA047904-07S1

CANCER CENTER SUPPORT GRANT

FWCI

0.16

Citation Percentile

0.5%

Citation Trend

2025

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11390298/pdf/nihms-2014566.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00280-024-04651-x.pdf

publisherhttps://link.springer.com/article/10.1007/s00280-024-04651-x/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11390298

Fields of Study

Histone Deacetylase Inhibitors ResearchHIV/AIDS drug development and treatmentProtein Degradation and Inhibitors03 medical and health sciences0302 clinical medicineHumansHydroxamic AcidsNeoplasmsSulfonamidesMaleModels, BiologicalFemaleMiddle AgedAntineoplastic AgentsLiver DiseasesAgedAdultMetabolic Clearance Rate

MeSH Terms

AdultAgedAntineoplastic AgentsFemaleHumansHydroxamic AcidsLiver DiseasesMaleMetabolic Clearance RateMiddle AgedModels, BiologicalNeoplasmsSulfonamides

Keywords

PharmacokineticsMedicinePharmacologyGlucuronidationNONMEMMetabolitePopulationDispositionInternal medicineDrug metabolismDrugOncologyGastroenterologyMicrosomeBiologyPopulation PharmacokineticsBelinostatParent-metabolite ModelingMaleAdultSulfonamidesMetabolic Clearance RateLiver DiseasesAntineoplastic AgentsMiddle AgedHydroxamic AcidsModels, BiologicalNeoplasmsHumansFemaleAged

Sustainable Development Goals

SDG 0: Good health and well-being

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

FAIR Checklist

Authors (10)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)